SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that interim results from an FDA-approved Phase I/II study of 10 patients with recurrent breast cancer treated with Inovio’s Selective Electrochemical Tumor Ablation (SECTA) therapy showed the therapy was safe, well-tolerated, and achieved a 75% complete tumor response rate.
